Public Growth Saluda Medical has progressed to a public company with a recent ASX IPO and a $150M funding uplift, indicating strong investor confidence and potential for larger-scale procurement of neuromodulation systems.

Advanced Sensing The EVA sensing technology integrated with the Evoke SmartLoop System represents a compelling upsell opportunity for clinics seeking closed-loop neuromodulation with real-time feedback and enhanced therapeutic precision.

Strategic Leadership New executive leadership as of mid-2025 signals a potential shift in sales strategy and enterprise partnerships; engage for channel alignment, global expansion, and enterprise deals.

US Market Focus Full commercial launch in the United States for EVA and related systems suggests a ripe bilateral market entry path and opportunities to position compatible hardware, service contracts, and training programs for U.S. care providers.

Clinical Momentum Active participation in high-profile neuromodulation events and presentation of new clinical data indicate ongoing validation and demand generation; target institutions attending NANS and similar conferences for demonstrations and pilot programs.